Evidence supporting the use of: Epigallocatechin gallate (EGCG)
For the health condition: Glaucoma

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Epigallocatechin gallate (EGCG), a major catechin found in green tea, has been investigated for its neuroprotective and antioxidant properties, which may be relevant in the context of glaucoma—a disease characterized by progressive optic nerve damage often associated with elevated intraocular pressure (IOP) and retinal ganglion cell (RGC) death. Several preclinical studies have demonstrated that EGCG can protect RGCs from oxidative stress-induced apoptosis in animal models of glaucoma. For example, research published in Experimental Eye Research and Nature has shown EGCG’s ability to reduce oxidative damage and inhibit pro-apoptotic signaling pathways in the retina. Some studies also suggest EGCG may lower IOP by improving aqueous humor outflow or by exerting anti-inflammatory effects.

However, the bulk of evidence comes from in vitro and animal studies; robust clinical trials in humans are lacking. There is no established dosage, formulation, or conclusive evidence demonstrating significant benefits in patients with glaucoma. Thus, while the mechanistic rationale is strong and early experimental results are promising, more clinical research is needed to validate EGCG’s efficacy and safety for glaucoma management in humans. At present, EGCG may be considered as a potential adjuvant, but not as a substitute for established therapies.

More about epigallocatechin gallate (EGCG)
More about Glaucoma